We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 20, 2020

Activity of Cabozantinib in Patients With Metastatic GIST After Treatment With Imatinib and Sunitinib

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Activity and Safety of the Multi-Target Tyrosine Kinase Inhibitor Cabozantinib in Patients With Metastatic Gastrointestinal Stromal Tumour After Treatment With Imatinib and Sunitinib: European Organisation for Research and Treatment of Cancer Phase II Trial 1317 'CaboGIST'
Eur. J. Cancer 2020 May 26;134(xx)62-74, P Schöffski, O Mir, B Kasper, Z Papai, JY Blay, A Italiano, C Benson, K Kopeckova, N Ali, P Dileo, A LeCesne, F Menge, S Cousin, E Wardelmann, A Wozniak, S Marreaud, S Litiere, F Zaffaroni, A Nzokirantevye, I Vanden Bempt, H Gelderblom

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading